Pathophysiology and recent advances in the management of renal osteodystrophy

Journal of Bone and Mineral Research

Volumn 17, Issue 12, 2002, Pages 2094-2105

  Elder, Grahame ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Bone mineral density; End stage renal disease; Parathyroid hormone; Renal osteodystrophy; Turnover markers

Indexed keywords

22 OXACALCITRIOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM SALT; CINACALCET; DEFEROXAMINE; PAMIDRONIC ACID; PARACALCITOL; PARATHYROID HORMONE[1-34]; PHOSPHATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; PARATHYROID HORMONE;

AMINO TERMINAL SEQUENCE; BIOPSY TECHNIQUE; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DENSITOMETRY; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; FRACTURE; GLOMERULUS FILTRATION RATE; HORMONE SUBSTITUTION; HUMAN; HYPERPARATHYROIDISM; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MORBIDITY; MORPHOMETRICS; OSTEOMALACIA; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; RENAL OSTEODYSTROPHY; REVIEW; SIDE EFFECT; BIOPSY; PATHOLOGY; PHYSIOLOGY;

BIOPSY; HUMANS; PARATHYROID HORMONE; RENAL OSTEODYSTROPHY;

EID: 0036895890     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2002.17.12.2094     Document Type: Review

References (137)

1. Fajtova VT, Sayegh MH, Hickey N, Aliabadi P, Lazarus JM, LeBoff MS 1995 Intact parathyroid hormone levels in renal insufficiency. Calcif Tissue Int 57:329-335.
2. Martinez I, Saracho R, Montenegro J, Llach F 1997 The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29:496-502.
3. Bricker NS, Slatopolsky E, Reiss E, Avioli LV 1969 Calcium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med 123:543-553.
4. Bricker NS 1972 On the pathogenesis of the uremic state. An exposition of the "trade-off hypothesis." N Engl J Med 286: 1093-1099.
5. Malluche HH, Ritz E, Lange HP, Kutschera L, Hodgson M, Seiffert U, Schoeppe W 1976 Bone histology in incipient and advanced renal failure. Kidney Int 9:355-362.
6. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, Gokal R 1993 Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 44:1071-1077.
7. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y 1993 Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436-1443.
8. Valimaki S, Farnebo F, Forsberg L, Larsson C, Farnebo LO 2001 Heterogeneous expression of receptor mRNAs in parathyroid glands of secondary hyperparathyroidism. Kidney Int 60:1666-1675.
9. Kifor O, Moore FJ, Wang P, Goldstein M, Vassilev P, Kifor I, Hebert SC, Brown EM 1996 Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 81:1598-1606.
10. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB 1997 Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 51:328-336.
11. Moallem E, Kilav R, Silver J, Naveh-Many T 1998 RNA-Protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 273:5253-5259.
12. Yamamoto M, Igarashi T, Muramatsu M, Fukagawa M, Motokura T, Ogata E 1989 Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat. J Clin Invest 83:1053-1056.
13. Naveh-Many T, Friedlaender MM, Mayer H, Silver J 1989 Calcium regulates parathyroid hormone messenger ribonucleic acid (mRNA), but not calcitonin mRNA in vivo in the rat. Dominant role of 1,25-dihydroxyvitamin D. Endocrinology 125:275-280.
14. Elder GJ, Kelly PJ, Eisman JA 1996 Effect of phosphate loading on the parathyroid-vitamin D axis in normal humans. J Bone Miner Res 11:S1:S484 (abstract).
15. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ 1996 Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534-2540.
16. Tominaga Y, Kohara S, Namii Y, Nagasaka T, Haba T, Uchida K, Numano M, Tanaka Y, Takagi H 1996 Clonal analysis of nodular parathyroid hyperplasia in renal hyper-parathyroidism. World J Surg 20:744-750.
17. Canalejo A, Hernandez A, Almaden Y, Concepcion MT, Felsenfeld A, Torres A, Rodriguez M 1998 The effect of a high phosphorus diet on the parathyroid cell cycle. Nephrol Dial Transplant 13(Suppl 3):19-22.
18. Kremer R, Bolivar I, Goltzman D, Hendy GN 1989 Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 125:935-941.
19. Parfitt AM 1997 The hyperparathyroidism of chronic renal failure: A disorder of growth. Kidney Int 52:3-9.
20. Zhang P, Duchambon P, Gogusev J, Nabarra B, Sarfati E, Bourdeau A, Drueke TB 2000 Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. Kidney Int 57:437-445.
21. Mora Palma FJ, Ellis HA, Cook DB, Dewar JH, Ward MK, Wilkinson R, Kerr DN 1983 Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med 52:332-348.
22. Malluche HH, Langub MC, Monier-Faugere MC 1999 The role of bone biopsy in clinical practice and research. Kidney Int 73(Suppl):S20-S25.
23. London GM, Fabiani F, Marchais SJ, de Vernejoul MC, Guerin AP, Safar ME, Metivier F, Llach F 1987 Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int 31:973-980.
24. Ritz E, Stefanski A, Rambausek M 1995 The role of the parathyroid glands in the uremic syndrome. Am J Kid Dis 26:808-813.
25. Rostand SG, Drueke TB 1999 Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56:383-392.
26. Smith JC, Page MD, John R, Wheeler MH, Cockcroft JR, Scanlon MF, Davies JS 2000 Augmentation of central arterial pressure in mild primary hyperparathyroidism. J Clin Endocrinol Metab 85:3515-3519.
27. Monier-Faugere MC, Malluche HH 1996 Trends in renal osteodystrophy: A survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 11(Suppl 3):111-120.
28. Coen G, Manni M, Addari O, Ballanti P, Pasquali M, Chicca S, Mazzaferro S, Napoletano I, Sardella D, Bonucci E 1995 Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: Effect of calcitriol treatment. Miner Electrolyte Metab 21:375-382.
29. Morrissey J, Rothstein M, Mayor G, Slatopolsky E 1983 Suppression of parathyroid hormone secretion by aluminum. Kidney Int 23:699-704.
30. Blumenthal NC, Posner AS 1984 In vitro model of aluminum-induced osteomalacia: Inhibition of hydroxyapatite formation and growth. Calcif Tissue Int 36:439-441.
31. Andress DL, Maloney NA, Endres DB, Sherrard DJ 1986 Aluminum-associated bone disease in chronic renal failure: High prevalence in a long-term dialysis population. J Bone Miner Res 1:391-398.
32. Hernandez D, Concepcion MT, Lorenzo V, Martinez ME, Rodriguez A, de Bonis E, Gonzalez-Posada JM, Felsenfeld AJ, Rodriguez M, Torres A 1994 Adynamic bone disease with negative aluminium staining in predialysis patients: Prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 9:517-523.
33. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV 1993 The spectrum of bone disease in end-stage renal failure-An evolving disorder. Kid Int 43:436-442.
34. Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E 1990 Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int 37:1522-1527.
35. Sherrard DJ 1995 Aplastic bone: A nondisease of medical progress. Adv Ren Replace Ther 2:20-23.
36. Piraino B, Chen T, Cooperstein L, Segre G, Puschett J 1988 Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 30:57-62.
37. Kurz P, Monier FM, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH 1994 Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Intl 46:855-861.
38. Hutchison AJ, Whitehouse RW, Freemont AJ, Adams JE, Mawer EB, Gokal R 1994 Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients. Am J Nephrol 14:19-29.
39. Mawad HW, Sawaya BP, Sarin R, Malluche HH 1999 Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 52:160-166.
40. Avram MM, Mittman N, Myint MM, Fein P 2001 Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 38:1351-1357.
41. Bianchi ML, Colantonio G, Montesano A, Trevisan C, Ortolani S, Rossi R, Buccianti G 1992 Bone mass status in different degrees of chronic renal failure. Bone 13:225-228.
42. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K 1999 Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084-1093.
43. Eeckhout E, Verbeelen D, Sennesael J, Kaufman L, Jonckheer MH 1989 Monitoring of bone mineral content in patients on regular hemodialysis. Nephron 52:158-161.
44. Heaf JG, Nielsen LP, Mogensen NB 1983 Use of bone mineral content determination in the evaluation of osteodystrophy among hemodialysis patients. Nephron 35:103-107.
45. Matuszkiewicz-Rowinska J, Skorzewska K, Radowicki S, Sokalski A, Przedlacki J, Niemczyk S, Wlodarczyk D, Puka J, Switalski M 1999 The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol Dial Transplant 14:1238-1243.
46. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C 2000 Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396-399.
47. Coco M, Rush H 2000 Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115-1121.
48. Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, Ball A, Weiss NS 2000 Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58:2200-2205.
49. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T 1999 Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287-293.
50. Drueke TB 1996 Abnormal skeletal response to parathyroid hormone and the expression of its receptor in chronic uremia. Pediatr Nephrol 10:348-350.
51. Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, Gokal R, Hoyland JA 2000 Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 58:1440-1449.
52. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D'Amour P 1998 A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 44:805-809.
53. Bianchi ML, Colantonio G, Campanini F, Rossi R, Valenti G, Ortolani S, Buccianti G 1994 Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 9:1595-1599.
54. Quarles LD, Lobaugh B, Murphy G 1992 Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145-150.
55. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, Hernandez A, de Bonis E, Darias E, Gonzalez-Posada JM 1995 Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int 47:1434-1442.
56. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y 1995 Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 26:836-844.
57. Urena P, de Vernejoul M 1999 Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 55:2141-2156.
58. Couttenye MM, D'Haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, De Broe ME 1996 Low serum levels of alkaline phosphatase of bone origin: A good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 11:1065-1072.
59. Malluche HH, Faugere MC, Fanti P, Price PA 1984 Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int 26:869-874.
60. Gao P, Scheibel S, D'Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL 2001 Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605-614.
61. Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A 2000 A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753-761.
62. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH 2001 Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460-1468.
63. Llach F, Massry SG 1985 On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin EndocrinolMetab 61:601-606.
64. Portale AA, Booth BE, Halloran BP, Morris RC Jr 1984 Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580-1589.
65. Ritz E, Kuster S, Schmidt-Gayk H, Stein G, Scholz C, Kraatz G, Heidland A 1995 Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure. Nephrol Dial Transplant 10:2228-2234.
66. Panichi V, Andreini B, De Pietro S, Migliori M, Taccola D, Giovannini L, Ferdeghini M, Palla R 1998 Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure. Clin Nephrol 49: 245-250.
67. Tsukamoto Y, Moriya R, Nagaba Y, Morishita T, Izumida I, Okubo M 1995 Effect of administering calcium carbonate to treat secondary hyperparathyroidism in nondialyzed patients with chronic renal failure. American Journal of Kidney Diseases 25:879-86.
68. Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E 1998 Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2. Am J Kidney Dis. 32:S48-S54.
69. Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y 2000 Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. American Journal of Kidney Diseases 35:458-64.
70. Block GA, Hulbert ST, Levin NW, Port FK 1998 Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617.
71. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK 2001 Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138.
72. CARI 2001 The CARI Guidelines (Caring for Australians with Renal Impairment). Australian Kidney Foundation and Australia New Zealand Society of Nephrology, www.kidney.org.au.
73. Tan CC, Harden PN, Rodger RS, Rowe PA, Spooner RJ, Junor BJ, Briggs JD 1996 Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol Dial Transplant 11:851-853.
74. Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP 1996 Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 45:111-119.
75. Ben Hamida F, El Esper I, Compagnon M, Moriniere P, Fournier A 1993 Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. Nephron 63:258-262.
76. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E 1996 Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int 49:163-167.
77. Oe PL, Lips P, van der Meulen J, de Vries PM, van Bronswijk H, Donker AJ 1987 Long-term use of magnesium hydroxide as a phosphate binder in patients on hemodialysis. Clin Nephrol 28:180-185.
78. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB 2000 Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483.
79. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM 2002 Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695-701.
80. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E 1999 A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694-701.
81. Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E 1999 A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18-26.
82. Weinreich T, Ritz E, Passlick DJ 1996 Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: Effects on bone mineral metabolism. Collaborators of the Multicenter Study Group. Perit Dial Int 16:260-268.
83. Kubrusly M, Gagne ER, Urena P, Hanrotel C, Chabanis S, Lacour B, Drueke TB 1993 Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int 44:551-556.
84. Brown AJ 2000 Mechanisms for the selective actions of vitamin D analogues. Curr Pharm Des 6:701-716.
85. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E 1997 A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 30:105-112.
86. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D 2001 Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol. Am J Kidney Dis 38(Suppl 5):S51-S56.
87. Okano T, Tsugawa N, Masuda S, Takeuchi A, Kobayashi T, Nishii Y 1989 Protein-binding properties of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a synthetic analogue of 1 alpha,25-dihydroxyvitamin D3. J Nutr Sci Vitaminol (Tokyo) 35:529-533.
88. Fan SL, Schroeder NJ, Calverley MJ, Burrin JM, Makin HL, Cunningham J 2000 Potent suppression of the parathyroid glands by hydroxylated metabolites of dihydrotachysterol(2). Nephrol Dial Transplant 15:1943-1949.
89. Frazao JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW 2000 Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 36:550-561.
90. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF 1998 Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040-4045.
91. Nemeth EF 1996 Calcium receptors as novel drug targets. In: Bilezkian JP, Raisz LG, Rodan GA (eds.) Principles of Bone Biology. Academic Press, San Diego, CA, USA, pp. 1019-1035.
92. Conigrave AD, Quinn SJ, Brown EM 2000 L-Amino acid sensing by the extracellular Ca2+-sensing receptor. Proc Natl Acad Sci USA 97:4814-4819.
93. Wada M, Nagano N, Nemeth EF 1999 The calcium receptor and calcimimetics. Curr Opin Nephrol Hypertens 8:429-433.
94. Antonsen JE, Sherrard DJ, Andress DL 1998 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53:223-227 (rapid communication).
95. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N 1998 NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53:448-453.
96. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J 2000 Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57:50-58.
97. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW 2000 A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436-445.
98. Drueke T, Cunningham J, Goodman WG, Horl WH, Braun J, Chen M-G, McCary LC, Steinhauslin-Jeanrenaud F, Turner SA, Ritz E 2001 Short-term treatment of secondary hyperparathyroidism with the calcimimetic agent AMG 073. J Am Soc Nephrol 12:764A (abstract).
99. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Brenner RM, Liu W, Turner SA, Bushinsky DA 2001 The calcimimetic AMG 073 reduces PTH and Ca x P in patients with secondary hyperparathyroidism. J Am Soc Nephrol 12:771A (abstract).
100. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ 1993 Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004-2011.
101. Massry SG, Coburn JW, Popovtzer MM, Shinaberger JH, Maxwell MH, Kleeman CR 1969 Secondary hyperparathyroidism in chronic renal failure. The clinical spectrum in uremia, during hemodialysis, and after renal transplantation. Arch Intern Med 124:431-441.
102. Machado CE, Flombaum CD 1996 Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 45:175-179.
103. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D'Agati VD 2001 Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12: 1164-1172.
104. Abdelhadi M, Nordenstrom J 1998 Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab 83:3845-3851.
105. Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Freemont AJ, Mawer EB, Gokal R 1992 Characteristics and natural history of adynamic bone disease in CAPD. J Am Soc Nephrol 3:673 (abstract).
106. Holgado R, Haire H, Ross D, Sprague S, Pahl M, Jara A, Martin-Malo A, Rodriguez M, Almaden Y, Felsenfeld AJ 2000 Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res 15:927-935.
107. Malluche HH, Smith AJ, Abreo K, Faugere MC 1984 The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure. N Engl J Med 311:140-144.
108. DeVita MV, Rasenas LL, Bansal M, Gleim GW, Zabetakis PM, Gardenswartz MH, Michelis MF 1992 Assessment of renal osteodystrophy in hemodialysis patients. Medicine 71:284-290.
109. D'Haese PC, Couttenye MM, Goodman WG, Lemoniatou E, Digenis P, Sotornik I, Fagalde A, Barsoum RS, Lamberts LV, De Broe ME 1995 Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant 10:1874-1884.
110. Pei Y, Hercz G, Greenwood C, Sherrard D, Segre G, Manuel A, Saiphoo C, Fenton S 1992 Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients. Kidney Int 41:1374-1382.
111. Ishii H, Wada M, Furuya Y, Nagano N, Nemeth EF, Fox J 2000 Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 26:175-182.
112. Calvo MS, Eastell R, Offord KP, Bergstralh EJ, Burritt MF 1991 Circadian variation in ionized calcium and intact parathyroid hormone: Evidence for sex differences in calcium homeostasis. J Clin Endocrinol Metab 72:69-76.
113. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH 1995 The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610.
114. Mitlak BH, Burdette-Miller P, Schoenfeld D, Neer RM 1996 Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat. J Bone Miner Res 11:430-439.
115. Przedlacki J, Manelius J, Huttunen K 1995 Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. Nephron 69:433-437.
116. Stehman-Breen CO, Sherrard D, Walker A, Sadler R, Alem A, Lindberg J 1999 Racial differences in bone mineral density and bone loss among end-stage renal disease patients. Am J Kidney Dis 33:941-946.
117. Stehman-Breen CO, Gillen D, Gipson D 1999 Prescription of hormone replacement therapy in postmenopausal women with renal failure. Kidney Int 56:2243-2247.
118. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD 1991 Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325:544-550.
119. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282.
120. Weber TJ, Quarles LD 2000 Preventing bone loss after renal transplantation with bisphosphonates: We can, but should we? Kidney Int 57:684-690.
121. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M 1998 Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: Implications for osteopenic disorders. J Bone Miner Res 13:371-382.
122. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH 2000 High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol 11:1093-1099.
123. Smets YF, van der Pijl JW, de Fijter JW, Ringers J, Lemkes HH, Hamdy NA 1998 Low bone mass and high incidence of fractures after successful simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 13:1250-1255.
124. Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Kirste G, Olschewski M, Schollmeyer PJ 1998 Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation 66:1004-1008.
125. Fan SL, Almond MK, Ball E, Evans K, Cunningham J 2000 Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57:684-690.
126. Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC 2001 Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12:1530-1537.
127. D'Alessandro AM, Melzer JS, Pirsch JD, Sollinger HW, Kalayoglu M, Vernon WB, Belzer FO, Starling JR 1989 Tertiary hyperparathyroidism after renal transplantation: Operative indications. Surgery 106:1049-1055.
128. Briner VA, Thiel G, Monier-Faugere MC, Bognar B, Landmann J, Kamber V, Malluche HH 1995 Prevention of cancellous bone loss but persistence of renal bone disease despite normal 1,25 vitamin D levels two years after kidney transplantation. Transplantation 59:1393-1400.
129. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO 2001 Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60:324-332.
130. Hafner J, Keusch G, Wahl C, Burg G 1998 Calciphylaxis: A syndrome of skin necrosis and acral gangrene in chronic renal failure. Vasa 27:137-143.
131. de Francisco AM, Ellis HA, Owen JP, Cassidy MJ, Farndon JR, Ward MK, Kerr DN 1985 Parathyroidectomy in chronic renal failure. Q J Med 55:289-315.
132. Papadakis JT, Patrikarea A, Digenis GE, Stamatelou K, Ntaountaki I, Athanasopoulos V, Tamvakis N 1996 Sodium thiosulfate in the treatment of tumoral calcifications in a hemodialysis patient without hyperparathyroidism. Nephron 72:308-312.
133. Zacharias JM, Fontaine B, Fine A 1999 Calcium use increases risk of calciphylaxis: A case-control study. Perit Dial Int 19:248-252.
134. Martin TJ 2000 Bisphosphonates-Mechanisms of action. Aust Prescrib 23:130-132.
135. Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, Bonucci E, Taggi F 1996 Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study. Nephrol Dial Transplant 11:813-819.
136. Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT 1995 Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 310:358-363.
137. Lafage MH, Combe C, Fournier A, Aparicio M 1992 Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 42:1217-1225.